ArticleDiscover oncology2025
Tissue-specific profiling of human protein phosphatases identifies G6PC1 as a liver cancer-selective biomarker.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Type II LDH/MDH Oxidoreductases in Pacific Oyster Magallana gigas (Thunberg, 1793): Gene Organization and Expression Patterns During Development and Across Tissues.Journal of molecular evolution · 2026Article
- The glucose-6-phosphatase system in cancer: from endoplasmic reticulum glucose-6-phosphate flux to stemness, immune escape, and therapeutic vulnerability.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein phosphatases are essential regulators of cellular signalling, yet their tissue-specific expression profiles and functional roles in cancer remain underexplored. This study aimed to systematically profile protein phosphatases expression across human tissues and malignancies to identify potential biomarkers. The transcriptomic data from GTEx, FANTOM, and HPA, were analysed assessing 265 protein phosphatases across 60 human tissues. Tissue specificity was quantified using the Tau index and coefficient of variation. Top candidates were further evaluated in TCGA and PCAWG cancer cohorts. Protein-level validation was performed using immunohistochemistry (IHC) data from HPA. Functional relevance was investigated through protein-protein interaction (PPI) network analysis and KEGG pathway annotations. G6PC1 emerged as the most liver-specific phosphatase (Tau > 0.99) with high inter-tissue expression variability. Its expression was sharply confined to liver tissue and retained in hepatocellular carcinoma (LIHC), with very low expression across other tumour types. IHC confirmed G6PC1 protein presence in liver cancer samples. PPI analysis positioned G6PC1 as a central metabolic regulator, interacting with key enzymes involved in gluconeogenesis and glucose homeostasis. Notably, G6PC1 expression remained stable across sex, age, tumour stage, ploidy, tumour purity, and tumour mutational burden (TMB) in PCAWG liver cancer patients. This integrative multi-omic analysis identifies G6PC1 as a highly liver-specific, biologically relevant, and potential diagnostic candidate for hepatocellular carcinoma. Its selective expression, protein-level detectability, and network centrality support its potential utility as a diagnostic candidate for liver cancer, warranting further experimental validation in independent clinical cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.